| > In   | tions:   | Benefis Health System  Benefis Hospitals  |
|--|--|---|
|  | itial each page and Sign/Date/Time last page   | PROVIDER ORDERS   |
| Diagnosis: _<br>Allergies wit                                  | h reaction type:   |   |
| 1. TREA CAPE CAPE COPE A. V B. E C. A D. II E. N F. If s G. If | ml exchanges<br>exchanges per day  | or sluggish drain and notify provider ample for cell count, gram stain, culture and |
|  | TONEAL EQUILIBRIATION: Test within 90 days of initiation of peritoneal dialysis  |   |
|  | DRATORY ROUTINE On admission (before first dialysis treatment):  1) Dialysis renal panel 2) CBC w/o differential 3) Hepatitis B surface antigen 4) Hepatitis C antibody 5) Hepatitis B surface antibody 6) Hepatitis B core antibody 7) HIV (after consent) 8) Iron profile 9) Ferritin 10) PTH Intact 11) ALT |   |
| В. М   | Monthly  1) CBC w/o differential  2) Dialysis renal panel  3) Iron profile  4) ALT   |   |

| BENEFIS I | HEALTH : | SYSTEM |
|-----------|----------|--------|
| Ве        | മ        | fic    |
| HOSP      |          |        |
|           |          |        |
|           |          | RDFRS  |

- 5) Hepatitis B surface antigen unless positive
- 6) Glucose (on all diabetic Patients)
- C. Quarterly
  - 1) PTH Intact
  - 2) Ferritin
  - 3) 24 hour urine for volume urea and creatinine
  - 4) 24 hour dialysate sample for urea and creatinine
  - 5)

| (place patient label here) |  |
|----------------------------|--|
| Patient Name:              |  |
|                            |  |
|                            |  |



PROVIDER ORDERS

## Order Set Directions

- $\rightarrow$  ( $\checkmark$ )- Check orders to activate; Orders with pre-checked box  $\boxtimes$  will be followed unless lined out.
- > Initial each place in the pre-printed order set where changes such as additions, deletions or line outs have been made
- Initial each page and Sign/Date/Time last page
- D. Semi-Annually:
  - 1) HgbA1C (if diabetic)
  - 2) Vitamin D 25 Hydroxy
- E. Annually:
  - 1) Hepatitis B surface antigen if antibody positive
  - 2) Hepatitis B surface antibody if vaccination series completed (If no response after booster, do not recheck)
  - 3) Hepatitis C antibody

## 4. ROUTINE MISCELLANEOUS

- A. On admission:
  - 1) Initiate hepatitis B Recombiant Vaccine (unless positive or allergic)
  - 2) PPD if no recent chest x-ray. If PPD positive obtain chest X-ray (reason for exam: positive TB skin test)
- B. Annually:
  - 1) TB questionnaire yearly. Notify Provider changes in results. TB test if traveling and receiving unit requires test. If positive TB test in past, CXR for possible TB.
  - 2) Influenza vaccine 0.5 ml IM
  - Pneumovax 0.5 ml IM if has not had, or if > 5 years since last given; MAX 2 doses
- D. Renal Diet:
  - 1) greater than 1.2 grams protein/kg/day, 2 grams Sodium, less than 1 gram phosphorus, less than 2 grams potassium, Fluid restriction of \_\_\_\_\_ ml/day
- E. Transfer Set changes every six months (January and July if possible)
- F. If patient presents with low drains problems, obtain KUB to check catheter placement.

## 5. DIALYSIS HEPATITIS B ORDERS:

- A. On all non-immunized patients, after obtaining consent, give 40 mcg Hepatitis B vaccine IM at month 0, 1,2,6.
- B. One month after 4th dose (month 7) draw Hepatitis B surface antibody. If antibody negative administer one additional dose of Hepatitis B vaccine at month 12.
- C. If previously vaccinated patient who was antibody positive converts to antibody negative repeat vaccine series once.
- D

## 6. MEDICATION ORDERS:

- A. Aranesp \_\_\_\_\_mcg sq every\_\_\_\_\_ weeks Adjust dose monthly using following Aranesp Protocol
  - 1) Aranesp is available is the following syringe sizes:
    - 25 mcg, 40 mcg, 60 mcg, 100 mcg, 150 mcg, 200 mcg and 300 mcg
  - 2) Target hemoglobin is 10-11.5 g/dL unless otherwise ordered
  - Maximum Aranesp dose is 300mcg/week or 1200 mcg/month. Notify provider if dose increase would be greater the maximum
  - 4) Monthly Aranesp dose adjustments:
    - a. Dose changes for Hgb 8-9.5 gm/dL

| Current Dose | New dose |
|--------------|----------|
| 25 mcg       | 60 mcg   |
| 40 mcg       | 100 mcg  |
| 60 mcg       | 150 mcg  |
| 100 mcg      | 200 mcg  |
| 150 mcg      | 300 mcg  |
| 200 mcg      | 300 mcg  |

| Initials |  |
|----------|--|
|          |  |

| (place patient label here) |
|----------------------------|
| Patient Name:              |
|                            |
|                            |

# BENEFIS HEALTH SYSTEM

**PROVIDER ORDERS** 

- Order Set Directions:  $> \qquad (\sqrt{\ }) \text{- Check orders to activate; Orders with pre-checked box } \boxtimes \text{ will be followed unless lined out.}$ 
  - Initial each place in the pre-printed order set where changes such as additions, deletions or line outs have been made Initial each page and Sign/Date/Time last page

b. Dose changes for Hgb 9.6-10 gm/dL OR Hgb decreases by greater than 0.5 gm/dL

| Current Dose | New dose |
|--------------|----------|
| 25 mcg       | 40 mcg   |
| 40 mcg       | 60 mcg   |
| 60 mcg       | 100 mcg  |
| 100 mcg      | 150 mcg  |
| 150 mcg      | 200 mcg  |
| 200 mcg      | 300 mcg  |

- Dose changes for Hgb 10.1-11 gm/dL: NO CHANGES
- d. Dose changes for Hgb 11.1-12 gm/dL OR increases is Hgb by greater than 0.5 mg/dL

| Current Dose | New dose   |  |
|--------------|--|--|
| 25 mcg       | ↑dosing interval by 1 week (ie if every 2 weeks change to every 3 weeks) |  |
| 40 mcg       | 25 mcg   |  |
| 60 mcg       | 40mcg  |  |
| 100 mcg      | 60 mcg   |  |
| 150 mcg      | 100 mcg  |  |
| 200 mcg      | 150 mcg  |  |
| 300 mcg      | 200mcg   |  |

- e. If Hgb is greater than 12 gm/dL
  - 1) Hold dose and notify provider.
  - 2) Repeat Hgb in 2 weeks
- 5) Aranesp dose adjustments for restarting after holding doses:
  - a. If Hgb is greater than 11.1-11.5 gm/dL

| Current Dose | New dose   |  |
|--------------|--|--|
| 25 mcg       | ↑dosing interval by 1 week (ie if every 2 weeks change to every 3 weeks) |  |
| 40 mcg       | 25 mcg   |  |
| 60 mcg       | 40mcg  |  |
| 100 mcg      | 60 mcg   |  |
| 150 mcg      | 100 mcg  |  |
| 200 mcg      | 150 mcg  |  |
| 300 mcg      | 200mcg   |  |

- If Hgb is 10.5-11 gm/dL: Restart at the same dose as before
- If Hgb is less than 10.4 gm/dL

| Current Dose | New dose |
|--------------|----------|
| 25 mcg       | 40 mcg   |
| 40 mcg       | 60 mcg   |
| 60 mcg       | 100 mcg  |
| 100 mcg      | 150 mcg  |
| 150 mcg      | 200 mcg  |
| 200 mcg      | 300 mcg  |

Initials\_\_\_\_\_

| (place patient label here) Patient Name: |
|--|
|  |

# BENEFIS HEALTH SYSTEM

PROVIDER ORDERS

- Order Set Directions:  $> \qquad (\sqrt{\ }) \text{- Check orders to activate; Orders with pre-checked box } \boxtimes \text{ will be followed unless lined out.}$ 
  - Initial each place in the pre-printed order set where changes such as additions, deletions or line outs have been made Initial each page and Sign/Date/Time last page

  - B. Gentamycin 0.1% cream to peritoneal dialysis catheter exit site daily.
  - C. Docusate Sodium 100 mg oral twice a day PRN for constipation
  - D. Venofer Administration Protocol:
    - 1) Iron studies monthly. Ferritin levels quarterly unless >1200 then monthly.
    - 2) If T-SAT <20, Ferritin <1200 ng/ml and Hgb <12.5 g/dL, give IV Venofer 300mg IV in 250ml NS over 1.5 hours on day 1 and day 14.
    - On day 28, give Venofer 400 mg IV in 250ml NS over 2.5 hours
    - 4) Hold Venofer for T-sat > 50% and Ferritin > 1200 ng/ml.
  - E. Vitamin D therapy
    - 1) Begin therapy only if these criteria are met:
      - a) Intact PTH >400 pg/ml
      - Serum calcium < 10.2 mg/dl
      - Serum phosphorus < 6.5 mg/dl

Suggested starting dose: Target PTH 150-600 pg/ml

| <u> </u>                   |       |                |                 |                |                |
|----------------------------|-------|----------------|-----------------|----------------|----------------|
| Intact PTH (pg/ml)         | < 400 | 401-600        | 601-800         | 801-1000       | > 1000         |
| Calcitriol oral dose DAILY | N/A   | <b>0.5</b> mcg | <b>0.75</b> mcg | <b>1.0</b> mcg | <b>1.5</b> mcg |

% PTH CHANGES =((Prior PTH - Current PTH)/ Prior PTH) X 100

| Laboratory Trend             | Dose Adjustment/Titration  |  |  |  |  |
|------------------------------|--|--|--|--|--|
| cCa 9.8 -10.2                | Decrease calcitriol dose by 0.25 mcg (if not already indicated to decrease based on PTH                  |  |  |  |  |
|                              | change)  |  |  |  |  |
| Or                           | Consider:  |  |  |  |  |
|                              | -reducing or discontinuing calcium based binder. Replace with a non-calcium based binder                 |  |  |  |  |
| If cCa increasing by 1 mg/dl | -additional education on low phosphorus and low calcium diet   |  |  |  |  |
| from previous value          |  |  |  |  |  |
| cCa >10.2                    | Hold calcitriol  |  |  |  |  |
|                              | Once cCa < 10.2 restart calcitriol dose at 0.25 mcg less than previous dose daily                        |  |  |  |  |
| Phosphorus > 6.5             | 1st time – Decrease calcitriol by 0.25 mcg daily   |  |  |  |  |
|                              | 2 <sup>nd</sup> time – Hold calcitriol, then restart at previous dose.                                   |  |  |  |  |
| PTH < 150                    | 1 <sup>st</sup> time – Decrease calcitriol by 0.25mcg daily  |  |  |  |  |
|                              | 2 <sup>nd</sup> time – Hold calcitriol, then restart once PTH > 200 at 0.25 mcg less than previous dose. |  |  |  |  |
|                              | -Evaluate binder, if on calcium based binder consider replacing with non-                                |  |  |  |  |
|                              | calcium based binder   |  |  |  |  |
| DTILLAGO COO (T)             | -Evaluate calcimemetic therapy. Consider reducing dose   |  |  |  |  |
| PTH 150-600 (Target)         | If PTH >400 and increased > 25% from last value: Increase Calcitriol dose by 0.25 mcg daily              |  |  |  |  |
|                              | If PTH decreased ≤25% from last value and previous PTH > 600. Maintain current calcitriol                |  |  |  |  |
|                              | dose   |  |  |  |  |
|                              | If PTH decreased >25% from last value and previous PTH > 600: Decrease current calcitriol                |  |  |  |  |
|                              | dose by 0.25 mcg 3x week   |  |  |  |  |
|                              | If PTH fluctuates within target range (150-600), maintain current calcitriol dose                        |  |  |  |  |
| PTH > 600                    | If PTH increased or decreased < 25% from last value: Increase calcitriol dose by 0.5 mcg                 |  |  |  |  |
|                              | dai;y  |  |  |  |  |
|                              | If PTH decreased 25-50% from last value: Maintain current calcitriol dose                                |  |  |  |  |
|                              | If PTH decreased > 50% from last value: Decrease calcitriol dose by 0.25 mcg daily                       |  |  |  |  |

ALL DOSE CHANGES MUST BE DOCUMENTED IN THE PROVIDER ORDERS

| Provider | Signature: | Date: | Time: |
|----------|------------|-------|-------|
|          |            |       |       |